June 3, 2021
Researchers are conducting a study to better understand and measure the impact of hypoglycaemia (low blood glucose) on the quality of life of people with diabetes and their loved ones.
Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin treatment. It is characterised by abnormally low blood sugar levels, which can lead to cognitive impairment and in some severe cases, seizures, loss of consciousness, coma and even death.
The Your SAY: Hypoglycemia study is an international research effort with the goal of assessing whether it matters how researchers ask questions about quality of life. The study is part of the Hypo-RESOLVE project, which aims to collect data to better understand and reduce the burden of hypoglycaemia.
The study consists of an online survey in English, with multiple-choice and short-answer questions, that targets people living with type 1 or type 2 diabetes and their loved ones. The survey takes about 30 minutes to complete.
Your SAY: Hypoglycemia provides an opportunity for people affected by diabetes to share their experiences, make their voices heard, and help others deal with the effects of hypoglycaemia.
The survey is open until August 2021. The criteria for participation are:
- Being 16 years or older
- Diagnosed with type 1 diabetes and living with the condition for at least six months, OR
- Diagnosed with type 2 diabetes and treated with insulin for at least six months, OR
- In a relationship and living with someone with diabetes who meets the above criteria.
The survey can be accessed on multiple devices at www.hypo-resolve.eu/haveyoursay
The Hypo-RESOLVE project has received funding from the Innovative Medicines Initative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries (EFPIA), T1D Exchange, Juvenile Diabetes Research Foundation (JDRF, International Diabetes Federation (IDF) and the Leona M. and Harry B. Helmsley Charitable Trust.